ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Diagonal Therapeutics launched with $128 million in series A financing. The company focuses on developing agonist antibodies. Instead of inhibiting a specific cellular function like conventional antibody treatments do, agonist antibodies bind two receptors together, activating them. According to the company, its Diagonal platform tests billions of possible receptor combinations. The company’s lead program is a treatment for hereditary hemorrhagic telangiectasia, a severe bleeding disorder.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X